Drugs / Iparomlimab and Tuvonralimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07289997 | Sep 2025 → Sep 2027 expected | gastroesophageal adenocarcinoma | Hebei Medical University Fourth Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab and Tuvonralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07289997 ↗ |
| Known as | QL1706 | “Iparomlimab and Tuvonralimab Injection (QL1706)” NCT07289997 ↗ |